Clinical Trials on Advanced Solid Neoplasm

Total 108773 results

University of California, San Francisco

Completed

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

FID-007 in Treating Participants With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Terminated

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Not yet recruiting

Adoption of Audio Recording in the Outpatient Supportive Care Center

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Institute of Nursing Research (NINR)

Active, not recruiting

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

Advanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Advanced Solid Tumors, Neoplasms, Advanced Solid

Hungary
Advanced Integrative Medical Science Institute

Recruiting

AIMS Cancer Outcomes Study (ACOS)

Neoplasms | Advanced Solid Tumor | Advanced Cancer | Oncology | Neoplasm Malignant

United States
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
AstraZeneca

Terminated

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Cancer | Advanced Solid Tumors | Advanced Solid Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Advanced Solid Neoplasm

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
Hoffmann-La Roche

Completed

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

Solid Tumors, Advanced Solid Tumors

United States
Esperance Pharmaceuticals Inc

Completed

Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors

Advanced Solid Tumors | Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
Amgen

Completed

A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy

United States, Australia
NantCell, Inc.

Completed

QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
Incyte Corporation

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Solid Tumors | Metastatic Solid Tumors

United States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Advanced Solid Neoplasm

United States
Merck Sharp & Dohme LLC
AstraZeneca

Recruiting

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Advanced Solid Neoplasms

United States, Argentina, Australia, Canada, Colombia, Denmark, France, Guatemala, Ireland, Israel, Japan, Korea, Republic of, Mexico, Peru, Romania, Russian Federation, Spain, Turkey, United Kingdom, Switzerland, Italy
Takeda

Completed

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid
Impact Therapeutics, Inc.

Recruiting

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

China, Taiwan, United States, Australia
GI Innovation, Inc.

Recruiting

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

Korea, Republic of, United States
Aadi Bioscience, Inc.

Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Advanced Solid Tumor | Tumor | Tumor, Solid

United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
Xenthera, Inc.

Not yet recruiting

Subjects With Advanced or Metastatic Solid Tumor Malignancies

Advanced Solid Tumor | Metastatic Solid Tumor

Clinical Trials on Advanced Solid Neoplasm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations